Table 1 Baseline patient characteristics at time of CML-MBP treatment initiation

Age, years

47 [29–83]

56 [37–89]

57 [21–79]

56 [27–74]

Race/ethnicity

 White, non-Hispanic

10 (50%)

14 (70%)

37 (66%)

5 (62.5%)

 White, Hispanic

4 (20%)

1 (5%)

2 (3.6%)

0

 Black

4 (20%)

4 (20%)

14 (25%)

3 (37.5%)

 Other

0

0

1 (1.8%)

0

 Not stated

2 (10%)

1 (5%)

2 (3.6%)

0

Initial CML presentation as de novo MBP

5 (25%)

5 (25%)

3 (5.3%)

0

Year of treatment initiation for MBP

2013

[2007–2018]

2013

[2003–2019]

2004

[2000–2012]

2003

[2000–2003]

Prior regimens for CML*

1 [0–3]

1 [0–4]

1.5 [0–5]

3 [0–4]

Prior TKI exposure

14 (70%)

14 (70%)

32 (60%)

7 (87.5%)

Changed TKI for MBP

10/14

7/14

30/32

N/A

BM blasts (%)

39 [21–87]

52 [24–91]

47 [20–87]

30 (20–60)

EM disease at diagnosis^

3/20 (15%)

0/20 (0%)

4/56 (7.1%)

2/8 (25%)

Additional clonal cytogenetic abnormalities

12 (60%)

15 (75%)

42 (75%)

6 (75%)

T315I mutation

3/20 (15%)

0/14 (0%)

1/23 (4.3%)

N/A

WBC (× 10⁹/L)

21.9 [3.1–259.3]

37.7 [1.0–156.6]

23.8 [0.7–363.7]

32.4 [2.4–319]

Platelet (× 10⁹/L)

127 [7–607]

75 [12–431]

82 [7–1128]

52 [21–2750]

Initial TKI for MBP

 Imatinib

0

7 (35%)

26 (48%)

N/A

 Dasatinib

10 (50%)

11 (55%)

12 (21%)

N/A

 Nilotinib

2 (10%)

1 (5%)

12 (21%)

N/A

 Bosutinib

1 (5%)

0 (0%)

3 (5%)

N/A

 Ponatinib

7 (35%)

1 (5%)

3 (5%)

N/A